Jiangsu Aidea Pharmaceutical Group Co., Ltd. (688488) has disclosed its intention to participate in a collective earnings presentation tailored for the innovative drug sector on the STAR Market, scheduled for the latter half of 2026.
According to an official announcement released on September 7, the company is set to join the event on September 16, 2026, from 3:00 PM to 5:00 PM. The session, organised by the Shanghai Stock Exchange, will serve as a platform for the semi-annual results review of innovative drug companies listed on the board.
This engagement underscores the company's commitment to transparent communication with investors and market participants, offering a comprehensive overview of its financial performance and strategic advancements during the reporting period.